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Abstract 
 
SLC10A4 (Solute carrier family 10 member 4) is a member of the sodium/bile acid co-
transporter protein family. Previous studies indicated that this protein is a   molecular link 
between two subpopulations of neurons i.e the monoaminergic and cholinergic. These 
neural subpopulations are widespread in the central nervous system (CNS) and are 
involved in most processes of our behaviour related to motivation, perseverance, reward 
system as well as all of the motor output. In this research study the focus has been on using 
Slc10a4 wild type (WT), knockout (KO) and Slc10a4 over expressing mouse, to 
characterize the function of a Vesicular Aminergic Associated transporter (VAAT) in 
cholinergic and dopaminergic neurons in the brain. Increased motor activity and increased 
drug-induced hyperactivity have been observed in KO mice. At subcellular level VAAT 
co-localizes with Vesicular Acetylcholine Transporter (VAChT) and Vesicular monoamine 
transporter (Vmat-2) on small synaptic vesicles (SV) at axon-termini in the brain. 
Experiments were performed to understand the significance of VAAT in cholinergic and 
dopaminergic systems, investigate VAChT distribution in neuromuscular junctions (NMJ) 
in VAAT mutant mice, study dopamine (DA) uptake efficiency in vesicles, investigate the 
epileptic link of VAAT and understand motor behavior of mutant mice. It was observed 
that VAAT colocalizes with VAChT in NMJ’s of diaphragm and gastrocnemius mouse 
muscles. The protocol for vesicular uptake studies was optimized under different 
conditions. Results illustrated that VAAT over-expressing mice show higher DA uptake 
compared to WT, while KO mice show less vesicular uptake. RNA expression analysis of 
muscarinic, nicotinic and dopaminergic receptors in striatum and hippocampus brain 
regions was performed. RT-qPCR results indicated no significant difference in expression 
levels; in both control and KO VAAT samples.  
 
Keywords: VAAT, VAChT, cholinergic, dopaminergic, synaptic vesicles, neuromuscular 
junctions, Slc10a4, dopamine uptake, striatum, hippocampus 
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1. Introduction 
 
It has been a challenging task for researchers to comprehend the intricate complexities of 
human brain. Neuronal circuits responsible for various body functions are an integral part of 
CNS. They are believed to play a key role in locomotory behavior, although its genetic 
basis still remains uncharacterized. Witnessing quite complex human behaviours in 
everyday life has instigated neuroscientists to ponder over several questions. Why do people 
respond in a certain fashion in distinct social situations? How does CNS coordinate with the 
brain through neural circuits in a fraction of seconds and instantly directs the body to act in 
a certain way? What makes people to promptly remove their hands from a hot surface, 
when they feel a burning sensation? What causes this instantaneous response? Why do 
animals including humans feel pain, fear and stress? What stimulates these explicit 
behavioural manifestations? Several simple and spontaneous behavioural responses still 
remain complex puzzles for scientists; they stand clueless about the fundamental underlying 
mechanism in which the CNS coordinates these behaviors. As researchers move closer to 
understand the principles of neuromodulatory systems in which human brain and CNS 
operate, it seems like a never-ending mirage. The unsolved mystery behind this continues to 
fascinate neuroscientists, prompting them to dwelve deeper to demonstrate enough 
substantial evidences to support their findings. Over the years significant advances in 
genetics have brought a revolution in the field of neuroscience, simplifying and expediting 
complex experiments to understand the neuronal connections. Several organisms like 
nematode worms, frogs, zebra fish, snails, fruitflies, rats, humans and mice have been used 
by scientists in different laboratories around the world, to study the dynamics of neural 
circuits. Although each promising breakthrough in neuroscience brings with it a ray of 
hope, the scientific community continues to raise more questions. This research study is an 
attempt to understand the everlasting enigma of CNS and neuronal circuits.  
 
 
1.1 Background 
 
The focus of research in the lab was on central pattern generators (CPG) in the CNS using 
mouse model. CPG’s are the neuronal circuits that control rhythmic movements, like 
breathing, chewing, feeding, swimming and walking. They have a significant role in 
locomotion and co-ordinating body movements (1). It has been observed that 
neuromodulators including neurotransmitters like DA, Serotonin, ACh, and Histamine, 
directly affect the output of physiological system by acting on CPG’s. These neuromuscular 
modulators act from neural inputs to develop contractions that result in muscular outputs 
(2). Multiple approaches were used to understand the role of neurotransmitters in distinct 
neuronal sub-populations. The identification of novel spinal cholinergic markers was a 
significant breakthrough, and a major turning point in itself. Gradually the research focus 
shifted to identifying subtype-specific genes for cholinergic neurons in the mouse spinal 
cord. Several methods were used, and 159 such genes, specific for cholinergic neurons were 
screened. A small subset of genes was shortlisted among these 159 genes, for detailed 
analysis. Microarray and in situ hybridisation (ISH) experiments were performed to identify 
exclusive cholinergic marker genes, Slc10a4 (Solute carrier family 10, member 4) was 
found to be one of those genes (3). Later Slc10a4 was also found to be present in 
dopaminergic neural subpopulations. Along with the identification of this orphan 
transporter protein, research interest switched further to investigating rudimentary function 
of Slc10a4 in different neuronal systems. Due to its exclusive vesicular location, this protein 
was named as Vesicular aminergic associated transporter or VAAT (4). The current study 
involves identifying function of Slc10a4, the fourth member of Slc10 family, in cholinergic 
and dopaminergic systems using mouse models. 
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1.2 Past studies on Slc10a4 
 
SLC10A4 belongs to the solute carrier super family consisting of more than 360 member 
proteins (5). Earlier Solute carrier family 10 (Slc10) was regarded to consist of only two 
sodium-dependent bile acid transporters SLC10A1 (also referred as Na+/taurocholate co-
transporting polypeptide or NTCP) and SLC10A2 (also known as apical sodium-dependent 
bile acid transporter or ASBT). Another four members SLC10A3, SLC10A4, SLC10A5 and 
SLC10A6 (known as Sodium dependent organic anion transporter or SOAT) were later 
included in the SLC10 family (6). SLC10A4 was originally discovered in 2004, as a 
hypothetical protein (7). The expression of Slc10a4 was found to be pre-eminent in nervous 
tissue; it was identified in different regions in humans, rats and mice. In Homo sapiens it 
was found in brain, eye, soft tissues and neuroblastomas, while in rodents it was present 
specifically in adrenal glands; in mouse it was identified in vascular system, ganglia, 
stomach, diencephalons, cortex, brain stem, eyeball and sympathetic ganglion. Although it 
shares highest phylogenetic relationship with sodium dependent bile acid transporter 
SLC10A1, it showed no transport activity for bile acids in the presence of sodium (8). 
Slc10a4 was cloned from the Rat adrenal gland (9). Immuno-fluorescence and co-
localization studies with cholinergic marker protein VAChT and monoaminergic marker 
protein VMAT2 revealed that SLC10A4 was found in both cholinergic and monoaminergic 
neurons in rat CNS and peripheral nervous system (10). Western blot (WB) studies also 
illustrated the presence of SLC10A4 in brain vesicles (9).  
 
 
1.3 VAAT as a molecular link between two distinct neuronal subpopulations 
 
Due to its expression pattern in the neuronal and non-neuronal cholinergic systems, it was 
hypothesised that SLC10A4 has a specialized function in regulation, release and storage of 
neuronal components like neurotransmitters, neuropeptides, or in exocytosis and retrieval of 
vesicles and granules (4). It was also assumed that both cholinergic and monoaminergic 
neurons share common functions in modulating behaviour. But to this date no genetic or 
biochemical discoveries linked these systems together. We proposed that VAAT could be 
considered as a significant molecular link between these two neuronal subpopulations. 
These widespread neural subpopulations in the CNS are implicated in behaviour related to 
motivation, perseverance, reward system as well as all of the motor output. Several 
independent studies investigated dopaminergic, cholinergic, adrenergic, and epileptic links 
of VAAT in mouse models at subcellular, vesicular, molecular and behaviour levels. ISH 
experiments were done to study the m-RNA expression pattern of VAAT in different 
neuronal populations and regions in brain and spinal cord. Electron Microscopy (EM) 
experiment was conducted to study terminal localization of Slc10a4. Stimulated Emission 
Depletion Microscopy (STED) was performed to find out whether VAAT colocalizes with 
VAChT or VMAT2 on same vesicles. In-situ proximity ligation assays (PLA) on enriched 
SV were performed to investigate vesicular co-localization of VMAT2 and VAAT with 
VAChT. Different behavior tests were conducted in VAAT WT and KO mouse to study 
neuromodulatory systems like Hanging wire test to analyse muscular strength, Elevated 
plus maze test to evaluate anxious behavior, Multivariate concentric square field test to 
analyze risk taking behavior, Eight-armed radial arm maze test to check learning and 
memory, and Locobox maze tests to measure locomotory behavior. High Performance 
Liquid Chromatography (HPLC) analysis was performed to determine concentrations of 
DA and its metabolites in Striatal brain tissues. DA turnover was calculated by evaluating 
synthesis, release, reuptake and metabolism of DA; and estimating the ratios between 
DOPAC (3, 4-Dihydroxy phenyl acetic acid), HVA (Homovanillic acid) and DA (4). 
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Electrophysiology experiments were conducted to identify the epileptic link of VAAT. The 
results obtained from these parallel studies were promising and supported our original 
hypothesis. The current project was designed to establish and connect the missing links on 
VAAT and further strengthen our presumptions, that VAAT has a specialised function in 
regulation and release of neuronal components. 
 
In this study the focus has been on using a WT, KO and VAAT over-expressing mice to 
understand VAAT functionality in cholinergic and dopaminergic neurons in the brain, and 
investigate its epileptic link. Slc10a4+/- mice were obtained from Texas A&M Institute, 
USA, after series of heterozygote breedings Slc10a4-/- mice were produced. Transgenic 
NSE-Slc10a4 mice were developed by incorporation of Slc10a4 c-DNA into mouse genome 
using genetic recombination tools. Experiments were performed to understand the 
significance of VAAT in cholinergic and dopaminergic systems, investigate VAChT 
distribution in NMJ’s in VAAT mutant mice, study DA uptake efficiency in SV, and study 
m-RNA expression analysis in striatal and hippocampus tissue.  
 
 
Dopaminergic link 
 
The neurotransmitter DA plays a significant role in brain functions that modulate behavior, 
movement, cognition, attention, learning, emotional response, pain and pleasure. DA 
containing neurons accumulate in the midbrain region, which is known as substantia nigra 
(11). Substantia nigra performs a key role in vital functions like reward, addiction and 
movement. Especially, pars compacta region supplies DA to the striatum, hence 
dopaminergic synapses can be found in the striatum (12). Membrane and vesicular 
transporter proteins for DA modulate neuronal activity. Dopamine active transporter (DAT) 
is responsible for reuptake of DA from synaptic cleft for recycling (13). Reuptake is 
necessary to inactivate DA action at postsynaptic targets. DAT has a significant function in 
DA homeostasis as observed in DAT mutant mice. It showed five times increase in 
extracellular DA content, while 95% decrease in Striatal DA content (14). Vesicular 
monoamine transporters (VMAT) 1 and 2 are vesicular proteins; VMAT2 specifically 
transports monoaminergic neurotransmitters into SV (15). Previous studies on VMAT2 null 
mutant mice exhibit abnormal storage and vesicular release properties in the animals. 
Aberrant DA activity has been associated with various neurological disorders (16). 
 
To investigate the role of VAAT in modulating DA homeostasis, SV purification and DA 
uptake studies were performed. The presence, absence and over expression of VAAT in 
respective animals were verified by vesicle enrichment and WB technique. Several 
modifications were done to the previous, established SV purification and uptake procedures. 
After conducting series of experiments using different uptake buffers, an exclusive protocol 
was standardized for DA uptake experiments.  
 
 
Epileptic link 
 
Several genetic studies in animals suggest that aberrations in synaptic proteins can result in 
different kinds of neurological disorders; Epilepsy is believed to be one of them. Previous 
studies established the presence of VAAT in cholinergic terminals. Another study also 
indicated altered locomotor activity and greater drug-induced hyperactivity in null mutant 
mice (4). Electrophysiology experiments revealed that carbachol; a cholinergic agonist 
impels gamma oscillations in hippocampal slices. These oscillations were observed in 
VAAT KO mice before treatment, and after injecting carbachol agonist, pilocarpine the 
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epileptic seizures grew rapidly. It was assumed that absence of VAAT gives rise to a greater 
response to cholinergic impetus (17). To investigate the epileptic link of VAAT further, and 
whether absence or presence of VAAT at receptor level significantly influences or gives 
rise to epileptic activity; we studied mRNA expression pattern in VAAT WT and KO mice. 
RT-qPCR experiments were done to check relative expression levels of various receptors in 
hippocampus and transporters in striatum regions of mice brain.  
 
Cholinergic link 
 
Cholinergic neurons are widespread in the peripheral and central nervous system, and play 
significant role in behavior modulation (18). NMJ is the synapse where the axon terminal of 
a motor neuron meets the motor endplate, the highly excitable region of muscle fiber 
plasma membrane responsible for initiating action potentials across the muscle’s surface, 
ultimately causing the muscle to contract. The signal passes through the NMJ via the 
neurotransmitter acetylcholine. Terminal branches expand outward from the motor nerve 
and emerge from their myelin sheath at the muscle to form terminals. These terminals are 
filled with synaptic vesicles, mitochondria, and tubules from smooth endoplasmic reticula. 
Synaptic terminals permit the necessary communication between motor neurons and their 
target muscles for muscle contraction (19). The motor end-plate is densely populated by 
acetylcholine receptors. This part of the research project involved co-localization studies of 
VAAT with VAChT in pure cholinergic synapses and analysis of VAChT distribution in 
NMJ’s of VAAT WT and KO mice using immunofluorescence. Diaphragm and 
gastrocnemius muscles of mice were selected for this study.  
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2. Aims of the project  
The main purpose of this research study was to understand the rudimentary function and 
biological significance of this recently discovered orphan transporter protein Slc10a4. It is 
found to be present in both cholinergic and dopaminergic neural sub-populations 
widespread in the CNS. It is widely known that both dopaminergic and cholinergic neuronal 
systems share common functions in modulating behavior, but no genetic discoveries link 
these systems together. It was assumed that VAAT could be considered as a significant 
molecular link between these two neuronal systems. It was also hypothesised that VAAT 
has a significant role in regulation, release, and storage of synaptic vesicles and 
neurotransmitters, like DA and ACh. Aberrations in synaptic proteins and neurotransmitter 
signalling are also often associated with neurological disorders, like epilepsy. This research 
project was thus designed to connect the missing links on VAAT by investigating the 
dopaminergic, cholinergic and epileptic links of VAAT in WT, KO and NSE-VAAT mouse 
models at subcellular, vesicular and molecular levels. Also, further analysis was required to 
provide additional insights on the potential role of VAAT and treatment possibilities in 
aminergic systems.  
1) Investigate Dopaminergic link – Dopaminergic signalling in the brain has a significant 
impact on our behavior related to motivation, reward, mood, attention, learning and motor 
behavior. It was hypothesized that VAAT has a significant role in modulating DA 
homeostasis and could reveal unexplored targets for curing neurological disorders. Thus, 
the purpose of this part of the research study was to elucidate the possible role of VAAT in 
pre-synaptic vesicles and its influence on DA signalling. To investigate further how the 
VAAT levels in synaptic vesicles affect DA uptake, a comparative analysis was performed 
by carrying out Synaptic vesicle assay studies in different vesicle samples extracted from 
the striatum regions of the brains of VAAT WT, KO and NSE-VAAT mice.  
2) Investigate Epileptic link - Epilepsy is believed to be one of the neurological disorders 
caused due to abnormality in synaptic proteins. Previous studies established the presence of 
VAAT in cholinergic terminals; they also indicated altered locomotor activity and higher 
drug-induced hyperactivity in null mutant mice. Electrophysiology experiments revealed 
that carbachol; a cholinergic agonist impels gamma oscillations in hippocampal slices. 
These oscillations were observed in VAAT KO mice before treatment, and after injecting 
carbachol agonist, pilocarpine the epileptic seizures grew rapidly. It was hypothesized that 
absence of VAAT gives rise to a greater response to cholinergic impetus. To further 
investigate and get a deeper insight of the epileptic link of VAAT, we studied mRNA 
expression pattern in VAAT WT and KO mice. RT-qPCR experiments were done to find 
out whether presence or absence of VAAT significantly affects epileptic activity.  
3) Investigate Cholinergic link – The axon terminal of a motor neuron meets the motor 
endplate at NMJ, the most excitable region of muscle fiber plasma membrane responsible 
for causing action potentials across the muscle’s surface, leading to muscular contraction. 
The signal moves through the NMJ via neurotransmitter acetylcholine. Acetylcholine 
significantly affects our Behavior and influences locomotion and coordination of body 
movements. Cholinergic link of VAAT was thus investigated to identify co-expression of 
VAAT with VAChT, in NMJ’s of diaphragm and gastrocnemius muscles of VAAT WT and 
KO mice. Co-localization studies of VAAT with VAChT in pure cholinergic synapses were 
performed and VAChT distribution was analyzed in NMJ’s using immunofluorescence.  
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3. Materials and Methods: 
 
3.1 SV purification, dopamine uptake and Western Blot studies 
 
VAAT WT, KO and NSE-VAAT Mice 
Slc10a4 WT, KO and Transgenic NSE-VAAT animals were used for DA uptake 
experiments. Slc10a4+/- mice (strain 129/SvEvBrd) were obtained from Texas A&M 
Institute for Genomic Medicine (College Station, TX, USA). Heterozygote breedings were 
setup to generate adult male and female homozygous mice and their WT littermate controls. 
Transgenic NSE-Slc10a4 (NSE-VAAT) mice were developed using genetic tools. The full 
length Slc10a4-cDNA (RIKEN clone E130304D01, Source Bioscience, Nottingham, UK) 
was inserted downstream of the rat neuron specific enolase (NSE, enolase 2) promoter, as 
depicted in Fig.1. HindIII linkers were attached to Slc10a4 c-DNA by Polymerase Chain 
Reactions (PCR) and cloned into the HindIII site of Pnse-Ex4 vector. Correct insert 
orientation was verified by PCR using primers: 5’-CTCTTGTCCACCCAAGGAGA and 
5’-GACCGGGACTAGAGGTGACA. Linearized NSE-Slc10a4 construct was purified and 
introduced to the genome by pronuclear injection at Uppsala University Transgenic Facility 
(UUTF). Founders were identified by PCR, and analyzed by ISH, Immunohistochemistry 
(IHC) and WB experiments. NSE-Slc10a4 was here referred to as NSE-VAAT animal. 
Guidelines by Swedish regulation and European Union Legislation were followed in 
keeping the mice. All animal experiments were conducted as approved by relevant animal 
ethics committee in Uppsala. Male and female mice between 7 and 24 weeks were used for 
vesicular experiments. Slc10a4-/- (VAAT mutant) mice were investigated with sibling WT 
mice as controls. Mice were killed by cervical dislocation and decapitation. Specific brain 
regions were dissected and rinsed in ice-cold homogenisation buffer. 
 
 
 
                            
                                  Fig.1 Transgenic NSE-VAAT model  
 
 
Primers  
For Genotyping Slc10a4 mice, following primers were used:  
WT_forward 5’-GGAAAGACATGGCTGACTCTG,  
WT_reverse 5’-CAGGTAAAGGGACCACAGG,  
KO_forward 5’-CAGGTAAAGGGACCACAGG,  
KO_reverse 5’-ACACCGGCCTTGTATTTGTAGC 
For TgNSE- Slc10a4 animals, following primers were used: 
forward 5’-CTCTTGTCCACCCAAGGAGA,  
reverse 5’-GACCGGGACTAGAGGTGACA.  
Maxima™ Hot Start Taq DNA Polymerase enzyme and PCR reagents were used for 
genotyping Slc10a4 animals.  
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Antibodies and Reagents 
Antibodies for WB were used in the following dilutions: Rabbit anti-Slc10a4 (Sigma 
Aldrich) 1:500, Guinea pig anti-Vacht (Millipore, MA, USA) 1:500, Synaptophysin 1:1000, 
VAAT 1:1000, Rpt-4 1:1000, HRP conjugated protein-A 1:5000,  
Loading dye (LD): 95% 4X Loading Buffer (containing 16% Sodium Do-decyl Sulphate 
content) 5% Beta-mercaptoethanol (Beta-m)  
Luminol Reagent (LR): LR A (5μl), LR B (1000μl), 3% Hydrogen peroxide (5μl) 
 
Genotyping 
Tail Prep: To extract genomic DNA, tail biopsies were first incubated in Tail-Prep Buffer 1, 
(volume of buffer added was according to the tail size). After 20 minutes at 95ºC, 450 RPM 
the samples were placed at room temperature for 5min. Subsequently equal amount of Tail-
Prep Buffer 2 was added. PCR was performed according to the protocol and program 
mentioned in Tables 2 and 3 incuded in the Appendix. PCR products were detected on 1% 
agarose gel, and mice genotypes were determined. 
  
Synaptic Vesicle Purification 
Standardization of Synaptic vesicle isolation and purification process was accomplished 
after extensive studies and modifications of previous protocols used by various researchers 
for SV purification in different animal models. Pioneering work on SV purification by 
Whittaker et al (20) from cerebral cortex in guinea-pigs; by Huttner et al (21) from Rat 
cerebral cortex; and by Jahn et al from Rat brains (22,23) was reviewed. Later protocols 
used by Teng et al (24), Takamori et al (25) and by Nickell JR et al (26) were also studied, 
and modified to design the final protocol. Biophysical principles, homogenization 
procedures, buffers and fractionation protocols used to isolate and purify vesicles were 
analysed. DA uptake efficiency in different uptake buffers like Jahn uptake buffer, Teng’s 
buffer and Kreb’s ringer buffer was compared. These buffers were originally tested in SV 
uptake experiments on other animal models, but in this current experiment they were being 
used on mouse models. Kreb’s ringer was identified as an ideal uptake buffer and used for 
further experiments. 
 
Three brains (excluding cerebellum and prefrontal cortex) were pooled and homogenized in 
15ml of ice-cold 0.32 M sucrose solution at 900 RPM with 10 up and down strokes of tight 
fitting Teflon homogenizer. Brain Lysate samples were separated and labelled as P1. The 
whole process was carried out at 4ºC. Cell debris, intact cells and nuclei separated in the 
form of pellet, when homogenate was centrifuged at 2.000 x g for 10 min. Supernatant was 
transferred to a separate tube and centrifuged at 15.000 x g for 15 min. Buffy coat pellet 
was dissolved in 2 ml of ice-cold 0.32 M sucrose and poured into a glass Teflon 
homogenizer containing 7 ml of deionized water to provide an osmotic shock. The 
suspension was homogenized within a minute at 2.000 RPM with 3 up and down strokes. 
Osmolarity was restored by adding 90 μl 1M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) pH 7.4 (KOH), 900 μl 1M potassium tartrate (pH 7.4) 
(KOH) and protease inhibitor (PI) cocktail (Roche Diagnostics Scandinavia). Pellet 
containing Synaptosomal fraction was separated in a tube and labelled as P2. A second 
centrifugation at 20.000 x g for 20 min was carried out to remove intact synaptosomes and 
other big membrane pieces. Intact vesicles and some contaminating organelles were 
obtained in the supernatant. The resulting supernatant was centrifuged at 55.000 x g for 60 
min to remove contaminating membrane pieces and bigger vesicular structures. Pellet 
containing large myelin membrane pieces of mitochondria and leftover intact synaptosomes 
was separated and labelled as P3. To the supernatant (100 μl) 0.01 M MgSO4, 0.25 M 
HEPES pH 7.4 (KOH), 1M Potassium tartrate pH 7.4 (KOH) was added and centrifuged at 
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100.000 x g for 120 min. The final pellet containing small synaptic vesicles was dissolved 
in 300 μl Krebs-Ringer buffer (in mM, NaCl 140, KCl 5, MgCl2 2, CaCl2 2, HEPES 10, 
sucrose 6, glucose 10, pH 7.4). Final vesicular fraction containing small synaptic vesicles 
was separated in a tube and labelled as P4. Protein content was quantified using Bradford 
assay (Appendix 10.2.2) and BSA as standard. 
 
Dopamine Uptake Process 
DA Uptake was initiated by incubating 15 μg protein equivalents of freshly prepared 
vesicles in 100 μl assay buffer (Krebs Ringer buffer with 50 nM [3H] DA (Perkin Elmer, 
Massachusetts, USA)) and 2 mM ATP-Mg final concentration at 32ºC for different time 
points. Triplicate samples were measured for different mouse samples, at every repeat. 
Uptake was stopped by dilution in 3 ml of wash buffer (in mM: 10 MOPS, 100 Potassium 
gluconate, 2 MgCl2). Non-specific uptake was measured after incubating SV in reserpine 
(200 nM) for 5 min at 32ºC before adding assay buffer, and by uptake performed on ice. 
Samples were filtered through Whatman GF/F filters (Whatman, Maidstone, UK) and 
washed with 5 ml of ice-cold wash buffer. Scintillation counter was used for counting of 
[3H] DA retained in the filters. Non-specific uptake was subtracted for each time point and 
genotype. Data counts for each sample were represented as percent of WT control counts 
after 16 min incubation period.  
  
Western Blot Studies 
WB experiments were performed to establish presence of VAAT in SV samples of NSE-
VAAT, VAAT WT & KO samples. Presence of vesicular protein Synaptophysin and RPT4 
was investigated in vesicle precipitates collected at different stages during SV purification 
process in different mice genotypes. These brain lysate samples were labelled as P1 (Brain 
Lysate samples), P2 (Synaptosomal fraction), P3 (Large myelin membrane pieces of 
mitochondria and left over intact synaptosomes) and P4 (Final enriched vesicle fraction 
containing small synaptic vesicles). Samples were prepared by adding loading dye 
(Composition mentioned in Section 4.1 Antibodies and Reagents), as it provides uniform 
charge to the protein; 1/4th volume (LD) of the total volume was added to the sample. Beta-
mercaptoethanol present in it, acts as a reducing agent, so the protein stays in a reduced 
form due to its presence. Samples were separated on 4-15% mini-PROTEAN TGX precast 
gel (Bio-Rad Laboratories AB, Sweden) at 121V for 1h. Subsequently, samples present in 
the gel were transferred on to a nitrocellulose membrane (Bio-Rad Laboratories AB, 
Sweden), at 15V for 30 min in a semi-dry electrophoretic transfer cell (Bio-Rad 
Laboratories AB, Sweden). Nitrocellulose membrane was blocked with 3% BSA for 1 h and 
incubated with primary antibody in blocking solution for 2 h at RT, followed by four 
washes in TBST (50 mM Tris pH 8, 150 mM NaCl, 0.05% Tween20). Membrane was 
incubated with protein A-HRP conjugates (Bio-Rad Laboratories AB, Sweden) for 1h at RT 
and washed in TBST. Then the membrane was treated with Luminol reagent, and the film 
was developed and printed in the dark room.  
 
 
 15 
 
3.2 Transcription studies 
 
VAAT WT and KO Mice 
Slc10a4 WT (+/+) and KO (-/-) animals were used for RNA expression studies. Striatum 
and Hippocampus tissues were specifically analysed in this experiment. 
 
Primers  
Primers for muscarinic receptors (M1, M2, M3, M4 and M5); nicotinic receptor (Chrna7), 
and dopaminergic receptors (D1 and D2) included in Table.1 in the Appendix; were used to 
study the m-RNA expression in WT and KO mice.  
 
Tissue Preparation and Homogenization 
Striatum and Hippocampus tissues were dissected from mouse brains. Tissue samples were 
homogenized in Tri-Reagent solution, using a pestle manually. Homogenate was incubated 
for 5 min at RT. It was centrifuged at 12.000 x g for 10 min at 4ºC, and supernatant was 
transferred to a fresh tube. 
 
RNA extraction  
Bromo-chloro-phenol (or BCP) (100μl/1ml of Tri-Reagent) was added to the tube 
containing supernatant and incubated at RT for 5-15 min. The mix was then centrifuged at 
12.000 x g for 10-15 min at 4ºC. Aqueous phase was then transferred to a new tube. 
 
RNA Precipitation and Wash 
Iso-propanol (500μl/1ml of Tri-reagent) was added to the tube containing aqueous solution, 
vortexed for 10 sec. and incubated at RT for 10 minutes. Tubes were then centrifuged at 
12.000 x g for 8 minutes at 4-25ºC, and supernatant was discarded. After discarding 
supernatant, 75% ethanol (1ml alcohol/1ml of tri-reagent solution) was added to the tube, 
and centrifuged at 75.000 x g for 5 min. Ethanol was removed and RNA pellet was air-dried 
briefly. Nuclease free water was then added to the tube containing RNA pellet. 
 
RNA quality check 
Agarose gel electrophoresis was performed to judge the integrity and overall quality of 
RNA samples by checking the 28S and 18S rRNA bands. The secondary structure of RNA 
alters its migration pattern in gels so that it will not migrate according to its true size. Bands 
are generally not as sharp as in denaturating gels, and a single RNA species may migrate as 
multiple bands representing different structures. RNA samples (1 µg) were loaded directly 
on 0.7 % agarose gels in TBE (89 mM Tris-HCl pH 7.8, 89 mM borate, 2 mM EDTA) with 
0.5 µg/ml ethidium bromide added to the buffer. Same amount of ethidium bromide was 
added in all the samples (including the size marker) because ethidium bromide 
concentration affects RNA migration in agarose gels. An aliquot of intact RNA was run as a 
positive control to rule out unusual results. The gel was run at 5-6 V/cm measured between 
the electrodes. 
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Genomic DNA contamination check and removal of genomic DNA  
After RNA quality check, the presence of contaminating gDNA was tested in the RNA 
samples. Housekeeping gene, Tubb5 primers were used to amplify RNA samples by 
running a PCR (Appendix Table 4 and 5). The quality of the starting template and its 
integrity can be determined by amplifying a housekeeping gene. The target gene(s) as well 
as housekeeping gene are co-amplified in the same reaction, eliminating the well-to-well 
variability that would occur if separate amplification reactions were carried out. These 
genes do not vary in expression between different samples. PCR products were then run on 
a gel to test the presence of contaminating gDNA in these RNA samples. Subsequently, 
RNA samples contaminated with gDNA were treated with DNase1, Protocol for DNase1 
treatment is provided in the Appendix in Table.6. Post DNase treatment another gel was run 
to check presence of gDNA in these samples. 
 
cDNA Synthesis  
cDNA was synthesised using reagents and protocols suggested in Invitrogen kit. Primers, d-
NTP’s and water were added to the extracted RNA samples. Mix was heated to 65ºC for 5 
min and quickly chilled on ice. Subsequently Buffer, DTT and RNase out reagent were 
added to the tube, mixed and incubated at 37ºC for 2 min. Reverse transcriptase was added, 
and the mix was incubated at 25ºC for 10 min. Tubes were further incubated for 50 min at 
37ºC, heat inactivated at 70ºC for 15 min, stored at -20ºC, and cDNA samples were diluted. 
 
Primer quality check  
Synthesized cDNA samples of hippocampus were used as templates to perform PCR on five 
muscarinic receptors, one nicotinic receptor and two dopaminergic receptors. Subsequently, 
the PCR products were run on an agarose gel to evaluate primer efficacy.  
 
Quantitative PCR experiments 
QPCR- SYBR Green (SG) mix, primers, water and cDNA were added to the PCR plate, 
using KAPA SYBR FAST qPCR Kit. The PCR program used for these experiments can be 
found in Table 7. Q-PCR Data was analysed using iQ5 software.  
 
 
3.3 Co-localization studies in Neuromuscular junctions 
 
VAAT WT and KO mice 
Slc10a4 WT (+/+) and KO (-/-) mice were used for co-localization studies of VAAT with 
Vacht in NMJ’s of Diaphragm and Gastrocnemius muscles. Two day old baby mice and 
adult mice were used for IHC experiments.  
 
Antibodies  
Primary antibodies used for IHC experiments were Guinea Pig Vacht (1:200), and Rabbit 
VAAT (1:500), while secondary antibodies used were Goat anti Guinea pig Cy3 (1:500), 
Donkey anti rabbit Alexa 647 (1:400), and Anti Btx (1:5000). 
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Tissue preparation 
Chat-Tom-Cre, Slc10a4 WT and KO mice were anesthetized with Isofluorane; according to 
body weight 100 μl/ 10 g sedative was administered to each mice. Phosphate buffered saline 
(PBS) solution with 4% formaldehyde was perfused by cardiac puncture in the heart. Once 
blood flow stopped, mice were dissected. Diaphragm and gastrocnemius muscles were 
removed and placed in 4% formaldehyde solution in PBS overnight (O/N). Prior to cryo-
sectioning, tissue was cryo-protected in 30% sucrose in PBS O/N, and embedded in tissue 
tek.  
 
Cryo-sectioning 
20 μm sections were collected in a cryostat (Microme HS, 560) on glass slides (Thermo 
Scientific, Superfrost plus) and stored at -20ºC until use. 
 
Immunohistochemistry 
IHC protocol was standardised by conducting test runs, PBStx and TBStx solutions were 
used separately to compare their individual efficiency. Slides processed using TBStx 
solution had superior results, compared to the ones processed using PBStx solution. So 
TBStx solution was used for further IHC experiments. Prior to Immuno-staining, slides 
were kept at room temperature for 30 min. Tissue tek was removed by placing the slides in 
TBStx (0.5% TritonX in TBS) for 10 min. Blocking solution (TBStx + 1% Bovine Serum 
Albumin (BSA) or Donkey serum) was applied for 1h to reduce unspecific antibody 
binding. Post blocking, slides were incubated with primary antibody diluted in blocking 
solution O/N at 4ºC. Unbound antibody was removed by TBStx washing. Slides were 
incubated with secondary antibody in TBStx for 45 min in dark, at RT. Secondary antibody 
was removed by TBStx washing. Triton-X was removed by TBS washing. Extra liquid was 
dabbed off from the slides, and they were mounted with Mowiol. Slides were kept in dark 
and cold. Fluorescence microscopy was used to view the immuno-staining in these sections.  
 
Image analysis 
Immuno-stained NMJ images captured using fluorescence microscope, were analysed using 
Image-J software. The degree of overlap or co-localization co-efficient of VAChT with 
VAAT in WT immuno-stained NMJ images was characterized (27). 
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4. Results 
 
4.1 Synaptic Vesicle Purification, Dopamine Uptake and Western Blot Studies  
 
WB studies were performed to investigate vesicle enrichment of vesicular protein 
Synaptophysin and non-vesicular protein RPT4. The SV enrichment results are shown in 
Fig.2. Blot indicates that Synaptophysin was present in different amounts from P1 to P4 
fraction, while RPT4 was present in almost equal amount from P1 to P3 fraction, while it 
was present in least amount in final vesicular fraction P4. 
  
         
Fig.2.  Western blot of Vesicular fractions P1, P2, P3 and P4 for detecting Vesicular protein 
Synaptophysin (SYP) and Non-vesicular protein RPT4. P1: Brain Lysate samples, 
P2: Synaptosomal fraction, P3: Large myelin membrane pieces of mitochondria left 
over intact synaptosomes, P4: Final enriched vesicle fraction containing small synaptic 
vesicles.  
 
The Presence of VAAT and Synaptophysin was determined (as 72 KDa and 38 KDa 
proteins) and detected in P4 vesicular precipitate (containing small synaptic vesicles) of 
VAAT WT, KO and NSE-VAAT mice using WB studies. As shown in Fig.3, VAAT was 
present in WT and NSE-VAAT samples in different amounts, while it was absent in KO 
sample. Synaptophysin was present in equal amounts in all three mouse genotypes.  
 
 
           
Fig.3.  Presence of VAAT (as 72 KDa mol. weight protein) and Synaptophysin (SYP as 38 
KDa protein) in protein extracts from Knockout (KO), Wild type (WT), and NSE-
VAAT (NSE) mice. For NSE mice, several dilutions (1, 1/5, and 1/10) were applied. 
Detection of the Proteins were performed by Western Blot using specific antibodies. 
 
DA uptake efficiency in Jahn uptake buffer, Teng’s buffer and Kreb’s ringer buffer was 
compared. The results are illustrated in Fig.4 and 5. 
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 Fig.4.  Comparison of DA uptake using (a) Jahn Buffer (b) Teng Buffer in different samples at 
different time points and temperatures. 
 
 
 
 
 
Fig.5. Comparison of DA uptake using (a) Teng Buffer (b) Kreb’s ringer Buffer in different 
samples at different time points and temperatures.  
 
DA uptake in vesicles from NSE-VAAT, WT and KO animals at different time points is 
illustrated in the form of a graph in Fig.6. Non-specific uptake determined in the presence 
of reserpine was deducted at each time point for all three genotypes. DA uptake was 
quantified and normalized according to control samples after removal of uptake in the 
presence of reserpine. Vesicles from VAAT null mice show less DA uptake while vesicles 
from NSE-VAAT mice show an increased uptake compared to vesicles from WT mice. No 
significant differences in DA uptake of different genotypes were seen at 8 min, because a 
saturation level was reached.  
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 Fig.6. Comparison of DA Uptake by NSE-VAAT, WT and KO samples. Solid line indicates 
uptake by NSE-VAAT samples, dashed line indicates uptake by WT samples, while 
dotted line indicates uptake by KO samples. Reserpine plot represents uptake shown by 
control samples of all three genotypes in the presence of reserpine. 
 
 
 
4.2 Transcription studies Results 
 
The relative m-RNA expression levels of transporters and receptors in Hippocampus and 
Striatum regions were checked in VAAT WT and KO animals. The m-RNA quality and 
contamination in RNA samples was checked at every step during the experiment. Primer 
efficiency of different primers was verified by running PCR, and Q-PCR experiments using 
those primers. The gel picture in Fig.7 corresponds to samples from different brain regions. 
In our actual experiment we took 7 WT and 7 KO samples (hippocampus or striatum) and 
did the same quality checks and gel runs.  
 
RNA prepared by Tri-reagent protocol was quality checked on an agarose gel. Quality of 
extracted RNA samples can be determined by the appearance of 28S and 18S discrete bands 
on an agarose gel. Crisp bands are indicative of intact m-RNAs the majority of which are 
between 2 Kb to 6 Kb in length, whereas smears trailing from 28S or/and 18S bands are 
indicative of degradation. RNA isolated in our case was intact as shown in Fig.7.  
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Fig.7. RNA samples isolated from different tissues. The upper band represents the 28S rRNA 
and the lower band the 18S rRNA. Samples were separated by gel electrophoresis as 
described in Materials and Methods. 
                           
Contamination with genomic DNA is a common problem while isolating RNA. Traces of 
gDNA can cause skewed quantitation of mRNA by RT-qPCR. RNA samples were used as 
templates to amplify Tubb5, a housekeeping gene to check gDNA contamination. The 
quality of the starting template and its integrity was determined in this experiment, by 
amplifying Tubb5. The target RNA as well as housekeeping gene is co-amplified in the 
same reaction, eliminating the well-to-well differences that would occur if separate 
amplification reactions were carried out. From all samples excluding skeletal muscle 
sample amplification products were obtained (Fig. 8), which indicate contamination in 
those RNA samples. Genomic DNA from a tail biopsy was used as a positive control.  
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 Fig.8. Genomic DNA contamination check in different RNA samples. Presence of gDNA 
confirmed in the form of band in all samples, except skeletal muscle sample.  
 
To remove genomic DNA contamination from RNA samples, DNase treatment was given 
to the contaminated samples as described in section 4.2. Post-DNase treatment a gel was 
again run to check the quality of RNA. The gel picture in Fig.9 shows smears in all the 
samples. This indicates that total RNA lost integrity during the DNase I treatment process. 
However, it was suggested that this degradation of total RNA should not create a problem 
because the amplicon size for the RT-qPCR primer pairs used varied between 80 bps to 200 
bps whereas the smear range was between 500 bps to 4000 bps. 
 
                
Fig.9.  Post DNase treatment, quality of different RNA samples checked; Smears observed on 
gel. 
 
After DNase treatment m-RNA samples were subjected to DNA contamination check as 
mentioned above; m-RNA samples were used as a template to amplify from Tubb5 primers 
and checked on the gel to monitor contamination. Gel picture in Fig.10 shows no bands in 
any of the RNA samples, which suggests that there was no contamination in the samples 
anymore. 
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Fig.10.  Genomic DNA contamination check of different RNA samples using Tubb5 primers, 
post DNase treatment. No gDNA bands in RNA samples confirm absence of gDNA 
after DNase treatment. 
 
All the primer pairs underwent efficiency check by running a PCR using same cDNA 
sample. Some size differences were observed for different amplicons (Fig.11). The 
amplification was considered to be efficient while no band was observed in the last well 
where Water sample was run, and primer pairs were used for Q-PCR experiments. 
 
  
 
            
Fig.11. Primer efficiency check of Dopaminergic receptor (D1), Muscarinic  receptors 
(M2, M3, M5), Slc10a4 (VAAT), housekeeping gene Tubb5, and Vesicular 
acetylcholine transporter (VAChT).  
 
Primers for different muscarinic receptors M1, M2, M3, M4 and M5; nicotinic receptor 
Chrna7, and dopaminergic transporters D1 and D2; were used to study the m-RNA 
expression in WT and KO mice. Q-PCR experiments were performed and the data obtained 
was further analysed using iQ5 software. Relative m-RNA expression levels of different 
receptors are shown in Fig. 12.  
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  Fig.12. Relative expression levels of Muscarinic (M1, M2, M3, M4, M5), and Nicotinic 
(Chrna7) receptors in Hippocampus and Dopaminergic (D1 and D2) transporters in 
striatum region of VAAT WT and KO mice. 
            
4.3 Immunohistochemistry Results 
 
By performing IHC experiments, the extent of distribution of vesicular transporter protein, 
VAChT was studied in 25 WT and KO NMJ images. Co-localization studies of VAChT 
with VAAT were done in pure cholinergic synapses and sections were immuno-stained for 
anti-bungarotoxin (Btx) (Green), anti-VAChT (Golden) and anti-VAAT (Red). Microscopic 
images of NMJ’s at different resolutions (400X, 630X and 200X respectively) were 
captured. Confocal images representing co-localization in gastrocnemius and diaphragm 
muscle sections of VAAT WT and KO mice; are illustrated in Fig. 13, 14  and 15. After 
analysis of 25 WT immuno-stained NMJ images using Image-J software, Pearsson’s co-
localization coefficient of 0.86 was obtained indicating 86% co-localization of VAChT with 
VAAT in WT NMJ’s.  
 
           
Fig.13. Two day-old gastrocnemius muscle NMJ’s (400X). First panel shows anti-Btx stained 
image, second panel illustrates anti-VaChT staining, third panel shows anti-VAAT 
stained image, while section in the fourth panel is a merged image of triple stained 
section, which indicates co-localisation of VaChT with VAAT. 
 
             
Fig.14. Adult gastrocnemius muscle NMJ’s (630X). First panel shows anti-Btx stained image, 
second panel illustrates anti-VAChT staining, third panel shows anti-VAAT stained 
image, while section in the fourth panel is a merged image of triple stained section, 
which indicates co-localisation of VAChT with VAAT.  
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Fig.15.  Adult Diaphragm muscle NMJ’s (200X). First panel shows anti-Btx stained image, 
second panel illustrates anti-VAChT staining, third panel shows anti-VAAT stained 
image, while section in the fourth panel is a merged image of triple stained section, 
which indicates co-localisation of VAChT with VAAT.  
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5. Discussion and Conclusion  
 
Vesicular-, RNA- and co-localization studies supported our hypothesis that VAAT is a 
novel transporter protein present in presynaptic vesicles of monoaminergic neurons, and is 
an important molecular link between dopaminergic and cholinergic neuronal systems.  
 
Vesicular studies strengthened the assumptions on the role of VAAT in DA homeostasis. 
These studies revealed that VAAT is present in pre-synaptic vesicles and fractions of pre-
synaptic vesicles. WB experiments confirmed the presence of VAAT, a 72 KDa protein in 
NSE and WT vesicle samples, while as expected, it was absent in VAAT KO samples. The 
Presence of Synaptophysin, a major vesicular protein was also confirmed in all three 
genotypes, in almost equal amount. Another WB depicted enrichment of Synaptophysin 
from P1 to P4 vesicular precipitate fractions. This suggests that the last vesicular precipitate 
fraction, P4 contains highest vesicular content, which implies that P4 also contains highest 
amount of VAAT.  
 
Remarkable difference was observed in DA uptake in different mouse genotypes at various 
time points. The transport of DA into synaptic vesicles was also affected by VAAT, where 
vesicles lacking VAAT showed a decreased vesicular DA uptake whereas over-expression 
of VAAT resulted in an increased uptake compared to controls. Thus, highest uptake was 
found in NSE-VAAT mice followed by WT samples, which show intermediate uptake, and 
least uptake was observed in VAAT KO samples. No significant difference in uptake was 
seen for 8min samples. These data suggest that mice lacking VAAT were found to have 
decreased striatal levels of DA. Thus loss of VAAT leads to less efficient DA vesicle 
uptake and decreased clearance of exogenously applied DA in vivo. The in-vivo functional 
analyses also suggested that the presence of VAAT enhances the efficiency of DA reuptake 
and to some degree also affects its release. These effects explain the higher DA 
concentrations which remain extracellular; and are in concert with the observed 
hyperactivity in VAAT mutant mice during behavior studies (4).  
 
It was also assumed that disturbed vesicular uptake could possibly occur due to several 
reasons. Change in pH could be attributed as one of them, to further investigate, Acridine 
orange experiment was performed by other researchers. Synaptic vesicles isolated from 
brains of NSE-VAAT displayed greater fluorescent quenching compared to vesicles from 
WT mice. No significant difference between VAAT null mice and WT were observed. 
Together these findings indicate that VAAT affects vesicular neurotransmitter filling 
properties, possibly through a greater ΔpH over the membrane. 
 
It has been observed in earlier electrophysiology studies that cholinergic system has 
important function in epileptic seizures. It was also observed during some parallel e-phys 
studies, that absence of VAAT increases the reaction to a cholinergic stimulus (17). But 
RNA expression studies of muscarinic, nicotinic receptor and dopaminergic receptors; in 
striatum and hippocampus regions, indicate no significant difference in relative m-RNA 
expression levels of VAAT KO and WT samples. The immunohistological analysis of 
gastrocnemius and diaphragm muscle sections, of post-natal and adult mice, provides 
evidence of co-expression of VAAT with VaCht. Co-localization of VAChT and VAAT 
was observed in NMJ’s; Subsequently Pearsson’s co-localization coefficient of VaCht with 
VAAT was found to be 0.86. Distribution of VaCht in WT and KO NMJ’s was studied and 
significant difference was not observed among them. This justifies the fact that no muscle 
related impairment or abnormality was observed in VAAT KO animals (4).  
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With these findings, it is concluded that VAAT has a significant molecular link between 
different aminergic neural subpopulations. VAAT is a vesicular transporter shared by the 
cholinergic and dopaminergic systems and adds functionality to dopaminergic neurons 
through a mechanism involving DA uptake into synaptic vesicles. It demonstrates a novel 
functional role for this unique transporter shared by aminergic neurons, through a 
mechanism likely to include the vesicular location of SLC10A4. The localisation of VAAT 
suggests analogous effects on other aminergic neurons. Immuno analysis suggests that 
VAAT colocalizes with VAChT in pure cholinergic synapses, at NMJ’s. Both 
monoaminergic and cholinergic neurons are involved in multiple nervous system diseases 
and the identified functional role of VAAT provides a novel target to modify the activity of 
dopaminergic neurons, and quite probable, all aminergic neurons. Moreover, the existence 
of VAAT raises the possibility of a commonly transported, and so far, unidentified 
molecule, which potentially is co-released with acetylcholine and monoamines. Mental and 
neurological diseases in humans are often associated with an imbalance between 
monoaminergic and cholinergic transmitters and further analysis of VAAT may thus offer 
additional insights into aberrant signalling in these two systems. The presence of VAAT 
protein was confirmed in mouse brain tissue, both by western blot analysis and in brain 
tissue sections. Thus, the function of VAAT described here could potentially be preserved 
in humans, indicating that the discovered role of this transporter is of relevance for normal 
human behaviour. 
 
 
 
 
 
 
 
 
 
 
 
 
6. Future work 
 
Future objective is to study electrical properties, pattern, amplitude and frequency of action 
potentials of acetylcholine synapses at neuro-muscular junctions, spinal cord and brain. 
Study acetylcholine uptake efficiency in synaptic vesicles. Perform RNA expression 
analysis of nicotinic receptors in different regions of brain, in VAAT KO and control 
samples. And perform detailed co-localization studies of VAChT with VAAT in WT 
NMJ’s.  
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9. Appendix 
9.1 Abbreviations 
1. ASBT - Apical sodium-dependent bile acid transporter 
2. ACh - Acetylcholine 
3. BCP – Bromo-Chloro-Phenol 
4. BL – Brain Lysate 
5. BSA – Bovine serum albumin 
6. Btx - Bungarotoxin 
7. Chat – Choline transporter  
8. cDNA – Complementary DNA 
9. CNS – Central Nervous System 
10. CPG – Central Pattern Generator 
11. Cy3 – Cyanine-3 
12. DA – Dopamine 
13. DAT – Dopamine active transporter 
14. DNA – De-oxy Ribonucleic acid  
15. DOPAC – 3, 4 Di-hydroxy phenyl acetic acid 
16. EM – Electron Microscopy  
17. HEPES - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
18. HPLC – High Performance Liquid Chromatography 
19. HVA – Homovanillic acid    
20. IHC – Immunohistochemistry 
21. ISH – Insitu hybridisation 
22. KO – Knock out 
23. LD- Loading dye  
24. m-RNA – Messenger Ribonucleic acid 
25. NTCP - Na+/taurocholate co-transporting polypeptide 
26. RNA – Ribonucleic acid  
27. NMJ – Neuromuscular junction 
28. NSE – Non specific enolase 
29. PBS – Phosphate buffered saline 
30. PCR – Polymerase Chain Reaction 
31. PLA - Proximity Ligation Assays 
32. RNA – Ribonucleic acid 
33. RPM – Revolutions per minute 
34. RT – Room temperature 
35. RT-PCR – Real time Polymerase Chain Reaction 
36. SDS – Sodium Do-decyl Sulphate 
37. SG – Sybr Green   
38. SOAT - Sodium dependent organic anion transporter  
39. STED – Stimulated emission depletion microscopy 
40. SV – Synaptic Vesicle 
41. TBS – Tris buffered saline solution 
42. TBStx – Tris buffered saline solution with triton-X 
43. UUTF - Uppsala University Transgenic Facility  
44. VAAT- Vesicular aminergic associated transporter protein 
45. VAChT – Vesicular acetylcholine transporter protein 
46. VMAT-2 – Vesicular monoaminergic associated transporter protein  
47. WB – Western Blot 
48. Wt- Wild type   
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9.2 Reagent Recipes 
 
9.2.1 Genotyping reagents 
 
Tail-Prep Buffer Recipe: 
10x Buffer 1:  
250 mM NaOH 
2 mM EDTA 
 
10x Buffer 2: 
400 mM Tris-HCl pH 8.0 
Adjust pH 8 by adding HCl 
 
 
9.2.2 SV Uptake Buffer Recipe 
  
Gluconate or Jan Buffer: 
Mops (10mM) – 2.09 g (10ml is added to the 1M solution prepared) 
K-Gluconate (100mM) – 23.42 g 
MgCl2 (2mM) – 0.4 g 
pH 7.3 (adjusted using KOH) 
 
Kreb’s Ringer-KCl solution: 
KCl 140 mM 
MgCl2 2 mM 
CaCl2 100 μl 
HEPES 10 mM 
Sucrose 6 mM 
Glucose 10 mM 
MQ water 
Adjust pH to 7.38 with KOH 
 
Bradford reagent: 
1 ml. Protein assay kept at 4ºC 
4 ml. Milli-Q water 
 
Assay Buffer: 
3HDA 8.35 μl  
ATP 16.5 μl  
Buffer A/B 1630 μl  
 
 
9.2.3 IHC Solutions 
 
TBS 10X (Concentrated Tris-buffered Saline, 1 liter) 
Tris base 24g 
NaCl 88g 
Dissolve in 900 ml DW 
Adjust pH to 7.6 with 12 N HCl 
Add DW to make a final volume of 1 liter 
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TBS 1X 
1 part of TBS 10X 
9 parts DW 
pH 7.6 
Final molar concentration of 1X solution is 20 mM Tris and 150 mM NaCl 
 
TBST (Tris-buffered saline with 0.1% Tween-20) 
100 ml TBS 10X 
900 ml DW 
1 ml Tween-20 
 
TBS 0.5% TritonX-100 
TritonX-100 500 μl 
pH 7.6 to 7.8 
 
Primary antibody diluent  
Na-azide 20 µl  
TBStx 49.5 ml 
1% BSA 0.5 ml 
 
9.2.4 Reagents used in Immuno-staining: 
 
Primary antibodies: 
Guinnea Pig-VAChT 1:200 
Rabbit-VAAT 1:500 
  
Secondary antibodies: 
Goat-Guinnea Pig Cy3 1:500 (Ex 554, Em 566) 
Donkey-Rabbit Alexa 647 1:400 (Ex 631, Em 647) 
Anti-Btx 1:5000 Alexa 488 (Ex 430, Em 450) 
 
Blocking solution:  
2% Na-azide (1:100) 500 μl 
5% Donkey serum 2.5 ml 
5% Goat serum 2.5 ml 
TBStx 44.5 ml 
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9.3 Tables 
 
Table 1. Primer pairs: 
  
    M1       forward GCACAGGCACCCACCAAGCAG   
      reverse AGAGCAGCAGCAGGCGGAACG   
    M2       forward GGCAAGCAAGAGTAGAATAAA   
      reverse GCCAACAGGATAGCCAAGATT   
    M3       forward GTCTGGCTTGGGTCATCTCCT   
      reverse GCTGCTGCTGTGGTCTTGGTC 
    M4       forward AGTGCTTCATCCAGTTCTTGTCCA    
      reverse CACATTCATTGCCTGTCTGCTTTG   
    M5       forward CTCATCATTGGCATCTTCTCCA   
      reverse GGTCCTTGGTTCGCTTCTCTGT   
    Chrna7       forward GCAGATCATGGATGTGGATG  
      reverse CAAGACGTTGGTGTGGAATG 
    D1       forward CAGTCCACGCCAAGAATTGCC  
      reverse ATTGCACTCCTTGGAGATGGAGCC 
    D2       forward GCAGCCGAGCTTTCAGGGCC   
      reverse GCAGCCGAGCTTTCAGGGCC 
 
 
Table 2. PCR Program followed for Genotyping: 
 
        STEP 1            95ºC           2 min 
        STEP 2            95ºC           30 sec 
        STEP 3            62ºC              40 sec 
        STEP 4            72ºC           40 sec 
        STEP 5    Go to STEP 2         32 times 
        STEP 6            72ºC            5 min 
        STEP 7              4ºC              ∞ 
 
 
Table 3.  PCR - mix (1x) 
                                                                                              
         Constituents         Final Concentration Volume (20 μl reaction) 
           10xBuffer                1x                       2 μl 
     (25 mM) MgCl2                           1.5 mM                                   1.2 μl 
     (10 μM) Fwd. Primer                  0.5 μM                                    1 μl 
     (10 μM) Rev. Primer                   0.5 μM                                     1 μl 
     (10 mM) d-NTP’s               0.25 mM                        0.5 μl 
     Enzyme (5 U/μl)           0.05 U/μl                 0.2 μl 
            DNA            100 ng/μl                    1 μl 
           Water                                      13.10 μl 
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Table 4. PCR program followed for RNA amplification:  
 
      STEP 1           95ºC           3 min 
      STEP 2           95ºC           30 sec 
      STEP 3           60ºC           30 sec 
      STEP 4           72ºC           45 sec 
      STEP 5    Go to STEP 2         35 times 
      STEP 6           72ºC           5 min 
      STEP 7           10ºC              ∞ 
 
 
Table 5. PCR – mix (1x) 
 
          Constituents       Final concentration   Volume (20 μl reaction) 
           10x Buffer                  1x                    2 μl 
       (25 mM) MgCl2                         1.5 mM                 1.2 μl 
  (10 μM) Fwd. Primer                       0.2 μM                 0.4 μl 
  (10 μM) Rev. Primer                       0.2 μM                 0.4 μl 
      (10 mM) d-NTP’s                0.2 mM                 0.4 μl 
      Enzyme (5 U/μl)             0.05 U/μl                 0.2 μl 
             RNA            200 ng/μl                    2 μl 
            Water                13.8 μl 
 
 
Table 6. DNase treatment protocol:  
 
          Constituents              Volume 
                 RNA                 4.5 g 
            10x Buffer                 2.5 µl 
        2 units DNaseI                    0.2 µl 
                 Water               17.3 µl 
 
 Mix RNA sample with Buffer and incubate at 75ºC for 10 min. Subsequently add 
enzyme and incubate the reaction-mix at 37ºC for 2 hrs. Deactivate the reaction by 
keeping the mix at 75ºC for 15 min. Incubate mix at 37ºC for 20 min. Stop DNase 
treatment by Trizol extraction.  
 
 
Table 7. QPCR program 
  
             STEP 1            95ºC           3 min 
             STEP 2            95ºC           3 min 
             STEP 3            60ºC           20 sec 
             STEP 4    Repeat 40 cycles  
             STEP 5             60ºC           1 min 
             STEP 6            65ºC           8 sec 
 
